S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
NASDAQ:MBRX

Moleculin Biotech (MBRX) Stock Price, News & Analysis

$0.61
-0.02 (-3.17%)
(As of 03/1/2024 ET)
Today's Range
$0.59
$0.65
50-Day Range
$0.46
$0.95
52-Week Range
$0.34
$1.65
Volume
126,754 shs
Average Volume
83,940 shs
Market Capitalization
$20.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Moleculin Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,209.3% Upside
$8.00 Price Target
Short Interest
Healthy
0.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Moleculin Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$159,999 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.87) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.65 out of 5 stars

Medical Sector

279th out of 950 stocks

Pharmaceutical Preparations Industry

124th out of 422 stocks


MBRX stock logo

About Moleculin Biotech Stock (NASDAQ:MBRX)

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

MBRX Stock Price History

MBRX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Oppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)
Moleculin Biotech Announces Positive Interim Data For Annamycin Trials
Moleculin Reports Third Quarter 2023 Financial Results
Moleculin Biotech Q3 2023 Earnings Preview
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/02/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$16.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,209.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.82 per share

Miscellaneous

Free Float
31,174,000
Market Cap
$20.41 million
Optionable
Not Optionable
Beta
1.98
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Walter V. Klemp (Age 64)
    Founder, Chairman, President & CEO
    Comp: $894.54k
  • Mr. Jonathan P. Foster CPA (Age 60)
    Executive VP & CFO
    Comp: $611.17k
  • Dr. Donald H. Picker Ph.D. (Age 78)
    Chief Scientific Officer
    Comp: $486.44k
  • Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP (Age 72)
    M.D., Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D. (Age 72)
    Sc.D., Senior Chief Medical Officer
  • Dr. Sandra L. Silberman M.D. (Age 69)
    Ph.D., Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A.
    M.D., Ph.D., European Chief Medical Officer
  • Ms. Jacqueline Northcut (Age 62)
    Consultant
    Comp: $51.11k
  • Mr. Louis Ploth Jr. (Age 70)
    Independent Advisor
    Comp: $118.49k














MBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price target for 2024?

3 equities research analysts have issued 12 month price objectives for Moleculin Biotech's stock. Their MBRX share price targets range from $3.00 to $16.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,209.3% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2024?

Moleculin Biotech's stock was trading at $0.8584 at the start of the year. Since then, MBRX stock has decreased by 28.8% and is now trading at $0.6110.
View the best growth stocks for 2024 here
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. During the same quarter in the previous year, the business posted ($0.24) earnings per share.

When did Moleculin Biotech's stock split?

Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.60%), Citadel Advisors LLC (0.19%) and Atticus Wealth Management LLC (0.17%). Insiders that own company stock include Jonathan P Foster, Robert E George and Walter V Klemp.
View institutional ownership trends
.

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MBRX) was last updated on 3/3/2024 by MarketBeat.com Staff